

## Oxbryta - (300 mg and 500 mg ; Tablet)

|                              |  |                             |                      |
|------------------------------|--|-----------------------------|----------------------|
| <b>Generic Name</b>          | Voxelotor  | <b>Innovator</b>            | Global Blood Theraps |
| <b>Dosage</b>                | 300 mg and 500 mg ; Tablet   | <b>Branded US Sales</b>     | Less Than \$1000 mn  |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5          |
| <b>Other ANDA developers</b> | Less Than 5  | <b>Tentative Approvals</b>  | None                 |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                 |
| <b>Indication</b>            | OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. |                             |                      |
| <b>Complexities</b>          | Yes  |                             |                      |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Oxbryta - (300 mg ; Tablets for Oral Suspension)

|                              |  |                             |                      |
|------------------------------|--|-----------------------------|----------------------|
| <b>Generic Name</b>          | Voxelotor  | <b>Innovator</b>            | Global Blood Theraps |
| <b>Dosage</b>                | 300 mg ; Tablets for Oral Suspension   | <b>Branded US Sales</b>     | Less Than \$1000 mn  |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5          |
| <b>Other ANDA developers</b> | None   | <b>Tentative Approvals</b>  | None                 |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                 |
| <b>Indication</b>            | OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. |                             |                      |
| <b>Complexities</b>          | Yes  |                             |                      |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.